LY288513
LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 produces an anxiolytic-like action in mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 147523-65-7
- Fòrmula: C22H18BrN3O2
- Peso molecular:436.30
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
IC50: 16 nM (CCK-B receptor)[1]
LY288513 (10 nM; 2 days) suppresses the effects of CCK-8 on CD4+ T cell subset-specific transcription factors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD4+ T cells
-
Concentration:10 nM
-
Incubation Time:2 days
-
Result:Suppressed the effects of CCK-8 on CD4+ T cell subset-specific transcription factors.
LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CD-l mice[3]
-
Dosage:3, 10 mg/kg; 10, 30 mg/kg
-
Administration:I.p.; p.o.
-
Result:Displayed anxiolytic-like effects in the elevated plusmaze.
Chemical Information
-
No. CAS 147523-65-7
-
Peso molecular 436.30
-
Fòrmula C22H18BrN3O2
-
SMILES
O=C(N1NC([C@@H](C2=CC=CC=C2)[C@@H]1C3=CC=CC=C3)=O)NC4=CC=C(Br)C=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann N Y Acad Sci. 1994 Mar 23;713:300-11. [Content Brief]
[2]. Zhang JG, et al. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. Int Immunopharmacol. 2014;20(2):307-315. [Content Brief]
[3]. Helton DR, et al. Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav. 1996 Mar;53(3):493-502. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LY288513 Related Classifications
HY-103357 Related Classifications
Powered by Bioz